FAM214A Inhibitors
Chemical inhibitors of FAM214A function through various mechanisms to disrupt the signaling pathways that the protein is involved in. Wortmannin and LY294002 are inhibitors that directly target the phosphoinositide 3-kinase (PI3K) pathway, which is an upstream activator of the Akt signaling pathway. Since the PI3K/Akt pathway is essential for numerous cellular processes, inhibiting this pathway with Wortmannin or LY294002 would lead to the functional inhibition of FAM214A, assuming it is a downstream component. Triciribine also targets the Akt pathway but does so by specifically inhibiting Akt itself, which would again result in the inhibition of FAM214A if it is part of this signaling cascade. In a similar vein, U0126 and PD98059 serve as inhibitors of MEK1/2, preventing the activation of the MAPK/ERK pathway. If FAM214A functions downstream of this pathway, the use of these inhibitors would impede its activity.
Further, Rapamycin, by binding to FKBP12, inhibits the mTOR pathway, a regulator of cell growth and proliferation. This would lead to the inhibition of FAM214A if it is connected to the mTOR signaling. SB203580 and SP600125 focus on stress response pathways, with the former inhibiting p38 MAP kinase and the latter inhibiting c-Jun N-terminal kinase (JNK). Inhibition of these kinases would impact the function of FAM214A if it is associated with cellular stress responses. Additionally, Sorafenib and Sunitinib act on multiple kinases involved in cell signaling, with Sorafenib targeting Raf kinases in the MAPK/ERK pathway and Sunitinib inhibiting receptor tyrosine kinases. The inhibition of these pathways would affect FAM214A's function related to cell signaling. Lastly, Dasatinib and Erlotinib target a range of tyrosine kinases, with Dasatinib inhibiting Src family kinases and Erlotinib targeting the epidermal growth factor receptor (EGFR) tyrosine kinase. The inhibition of these kinases and their associated pathways can lead to the functional inhibition of FAM214A if it is involved in the signaling pathways regulated by these kinases.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin inhibits phosphoinositide 3-kinases (PI3K), which are upstream of Akt signaling. FAM214A, being part of the intracellular signaling cascade, is functionally inhibited as PI3K/Akt pathway activation is necessary for multiple cellular processes including those potentially involving FAM214A. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another inhibitor of PI3K, leading to the inhibition of Akt phosphorylation and activation. PI3K pathway is crucial for the regulation of various cellular processes, and the inhibition by LY294002 would result in the functional inhibition of FAM214A if it operates downstream of this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and inhibits the mTOR pathway, which is implicated in cell growth and proliferation. FAM214A, being potentially connected to cell growth, would be functionally inhibited due to the blockade of mTOR signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific inhibitor of MEK1/2 which blocks the activation of ERK1/2. As FAM214A may be involved in the MAPK/ERK pathway, the inhibition of MEK would lead to a downstream functional inhibition of FAM214A. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase, another pathway that could be crucial for FAM214A's function in response to stress signals. Inhibition of p38 MAPK would therefore inhibit FAM214A's function related to stress response. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in cellular stress and apoptosis. The inhibition of JNK can lead to functional inhibition of FAM214A if it is part of stress response signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK1/2, preventing the activation of the MAPK/ERK pathway. The functional inhibition of this pathway would inhibit FAM214A's role, assuming it is involved in the MAPK/ERK pathway. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically inhibits Akt, which may be involved in signaling pathways regulating cell survival and proliferation. Inhibition of Akt would result in the functional inhibition of FAM214A if it is part of the PI3K/Akt pathway. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor that inhibits multiple targets, including Raf kinases involved in the MAPK/ERK signaling pathway. The inhibition of this pathway would functionally inhibit FAM214A if it is involved in cell proliferation processes regulated by MAPK/ERK. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor that targets pathways involved in tumor growth and angiogenesis. The functional inhibition of these pathways would inhibit FAM214A if it plays a role in these cellular processes. | ||||||